Form 4: Precision Biosciences Director Geno Germano Reports Routine Equity Compensation Transactions

Precision Biosciences Director Geno J. Germano reported the vesting of 9,826 Restricted Stock Units into common stock and the grant of 21,000 new Restricted Stock Units.

Summary

• Geno J. Germano, a Director of Precision Biosciences Inc. (DTIL), reported changes in his beneficial ownership of company securities.
• On May 27, 2025, 9,826 Restricted Stock Units (RSUs) vested, converting into 9,826 shares of Common Stock. This increased his direct beneficial ownership of Common Stock to 20,883 shares.
• On June 3, 2025, Mr. Germano was granted an additional 21,000 Restricted Stock Units.
• Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
• The newly granted 21,000 RSUs are set to vest on the earlier of June 3, 2026, or the day immediately prior to the Issuer's next annual meeting of stockholders following the grant date, subject to continued service.

Sentiment

Score: 7

Explanation: The filing indicates routine equity compensation for a director, including the vesting of existing RSUs and the grant of new ones. This is a standard practice for executive and director compensation, generally viewed as a positive for executive retention and alignment of interests, without indicating any unusual or negative corporate events.

Positives

• The vesting of 9,826 Restricted Stock Units (RSUs) into common stock represents a realization of previously granted equity compensation for the director.
• The grant of an additional 21,000 RSUs indicates ongoing equity compensation for the director, aligning his interests with long-term shareholder value.

Future Outlook

The newly granted 21,000 Restricted Stock Units are scheduled to vest on the earlier of June 3, 2026, or the day immediately prior to the Issuer's next annual meeting of stockholders following the grant date, contingent on the director's continued service.

Industry Context

This Form 4 filing reflects routine equity compensation for a director, which is a common practice across industries, including the biotechnology sector, to attract, retain, and incentivize key personnel by aligning their financial interests with the company's performance.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a form of equity compensation for directors is a standard practice in the biotechnology and broader public company landscape, comparable to compensation structures at companies like Editas Medicine (EDIT) or CRISPR Therapeutics (CRSP) for their non-employee directors.
• The vesting schedule tied to continued service and future annual meetings is also a common mechanism to ensure long-term commitment and alignment.

Related Party Transactions

• The transactions represent standard equity compensation provided by Precision Biosciences Inc. to its director, Geno J. Germano, which is a common form of related party transaction in the context of executive and director compensation.

Stakeholder Impact

• Shareholders: The vesting of RSUs leads to a slight increase in outstanding shares, which is an expected and minor dilutive effect from ongoing equity compensation plans. The grant of new RSUs aligns the director's interests with long-term shareholder value.
• Employees: No direct impact on general employees is indicated by this filing.
• Director (Geno J. Germano): Benefits from increased direct ownership of common stock and future equity compensation, enhancing personal wealth and aligning incentives with company performance.

Next Steps

• The 21,000 Restricted Stock Units granted on June 3, 2025, are expected to vest on the earlier of June 3, 2026, or the day immediately prior to the Issuer's next annual meeting of stockholders following the grant date, subject to continued service.

Key Dates

Keywords

Precision Biosciences, DTIL, Form 4, Insider Transaction, Restricted Stock Units, Equity Compensation, Director Compensation, Stock Ownership, Geno Germano